Clinical Pearls for Community Oncologists Treating Myelofibrosis
The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Unmet Needs in Myelofibrosis Treatment
Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.
Sequencing Treatments for Myelofibrosis
A look at sequencing strategies for myelofibrosis treatments.
Assessing Response to Treatment in Myelofibrosis
Dr Srdan Verstovsek shares how he assesses myelofibrosis treatment response in his clinical practice.
Considering Toxicities when Choosing Appropriate Treatment for Myelofibrosis
Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.
Approaches to Switching Treatments for Myelofibrosis
A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.
Clinical Scenario: Myelofibrosis Treatment in the Second-Line Setting
John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.
Treatments for Myelofibrosis Based on Platelet Counts
A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.
Therapy Strategies for Primary Myelofibrosis
Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.
Approved Treatments for Myelofibrosis
A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.
Clinical Scenario: Patient with Primary Myelofibrosis
Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.
The JAK/STAT Pathway and Myelofibrosis
Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.
Differences Between Types of Myelofibrosis
Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.
Diagnosis and Risk Stratification of Myelofibrosis
Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.
Optimizing Therapy for Patients With Myelofibrosis
Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.
Individualizing Therapy for Patients With Myelofibrosis
Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.
Second-Line Therapy for High-Risk Primary Myelofibrosis
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.
Second-Line Treatment Options for Myelofibrosis
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
Pharmacotherapy for Myelofibrosis
Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.
Treatment Planning and Myelofibrosis
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
Symptom Assessments in Myelofibrosis
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.
Pathophysiology of Myelofibrosis
The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.
2 Clarke Drive Cranbury, NJ 08512